Singapore biotechnology startup Tetris Therapeutics has raised $15 million from the funds managed by Trinity Innovation Bioventure Singapore (TIBS) and its affiliates to develop antibody drug conjugates (ADCs) that aim to address unmet medical needs. ADCs are one of the fastest growing fields in cancer therapy with market size projected to grow at a compound annual growth rate of 24% over the period of 2022 to 2029. Global sales of currently marketed ADCs are forecast to exceed S$16.4 billion in 2026.

Established in March 2022, Tetris Therapeutics is a platform-based biotechnology company and firmly believes that ADC is the long-awaited solution to cancer.

Funding from this seed round will be used to expand the team, establish the technology platform and develop a robust pipeline. Tetris Therapeutics is currently setting up research and development facilities in Singapore.

In addition to establishing Tetris Therapeutics, Dr. Zou is an adjunct associate professor at National University of Singapore and Nanyang Technological University. He is a serial entrepreneur and was the founder and CEO of Shanghai Blueray Biopharma. Under his leadership, he successfully led the team to develop several candidates into the investigational new drug (IND) stage. Prior to his venture, Dr. Zou started his career as a principal scientist at Novartis Institute for Tropical Disease and discovered Phase II clinical trial drug NITD609.